Principles of Outpatient COVID-19 Management

Principles of Outpatient COVID-19 Management

Thursday, October 6, 2022
Webinar -- 6:00 PM ET
https://www.clinicaloptions.com/C19earlyoutpatientJoin2

Agenda

  • Current state of COVID-19
  • Timely COVID-19 diagnostic and treatment strategies
  • Risk stratification and timely determination of candidates for antiviral treatment
  • Current landscape of COVID-19 antiviral therapies
  • Benefits of early outpatient antiviral therapy for mitigation of SARS-CoV-2 deleterious consequences (eg, acute and long-term sequelae)
  • Question and answer session

Faculty

Faculty
Renslow Sherer, MD

Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Faculty
Trinh Vu, PharmD, BCIDP

Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmaceutical Services
Emory University Hospital Midtown
Atlanta, Georgia

 

 

Goal Statement
The goal of this activity is to improve healthcare professionals’ knowledge and competence and foster an interprofessional approach for early SARS-CoV-2 diagnosis and treatment in the outpatient setting to mitigate severe and long-term consequences of COVID-19.

Target Audience
This program is intended for physicians, nurses, nurse practitioners, pharmacists, and other healthcare professionals involved in the management of patients with COVID-19, including both specialists and primary care providers. This identified target audience will benefit from this education by gaining the knowledge and strategies necessary to individualize early outpatient COVID-19 management.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recognize the need for timely COVID-19 testing, diagnosis, and risk stratification at or before the onset of symptoms
  • Describe the rationale for outpatient SARS-CoV-2 antiviral therapy early in the disease course
  • Identify candidates for early outpatient treatment with SARS‑CoV‑2 antivirals based on determinants associated with adverse outcomes including risk factors for severe illness and health disparities

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), ProCE, LLC, and Practicing Clinicians Exchange. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-22-205-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO), ProCE, LLC, and Practicing Clinicians Exchange (PCE), require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO, ProCE, and PCE policy. CCO, ProCE, and PCE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.